Sugi Predict

Sugi Predict / Compounds / SCHEMBL965883

SCHEMBL965883

SCHEMBL965883

C=CCN[C@H](C(=O)O)[C@@H](C)CC

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ FPR2 P25090 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ MAPK1 P28482 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CA2 P00918 4/20 0.37
▸ CA1 P00915 3/20 0.37
▸ MME P08473 1/20 0.37
▸ ACE P12821 1/20 0.37
▸ CPA1 P15085 1/20 0.37
▸ ACE2 Q9BYF1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29981567 1.00 ALDH1A1 (0.50) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL965882 1.00 ALDH1A1 (0.50) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL10714657 0.83 TSHR (0.38) ALDH1A1KMT2ACYP2C19CPA1
SCHEMBL10589733 0.82 ALDH1A1 (0.36) ALDH1A1KMT2AATMCA2CA1
SCHEMBL10589738 0.82 ALDH1A1 (0.36) ALDH1A1KMT2AATMCA2CA1
SCHEMBL30552195 0.77 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL250458 0.77 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL250457 0.77 ALDH1A1 (0.59) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL629450 0.76 ALDH1A1 (0.42) ALDH1A1L3MBTL1FPR2MEN1KMT2A
SCHEMBL614517 0.76 ALDH1A1 (0.36) ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110799547-A Compounds for treating, ameliorating or preventing neurological-related disorders and uses thereof 拜西欧斯（北京）生物技术有限公司 2020-02-14 — — CN claimed
WO-2024151890-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PROFOUNDBIO US CO. (US) 2024-07-18 — — WO disclosed
US-20240207418-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PROFOUNDBIO US CO. 2024-06-27 — — US disclosed
US-20240207429-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-06-27 — — US disclosed
EP-4366777-A2 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PROFOUNDBIO US CO. (US) 2024-05-15 — — EP disclosed
WO-2024074813-A1 A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT OWLSTONE MEDICAL LIMITED (GB) 2024-04-11 — — WO disclosed
WO-2023222682-A1 PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2023-11-23 — — WO disclosed
CN-110799547-B Compounds for treating, ameliorating or preventing neurological-related disorders and uses thereof 拜西欧斯（北京）生物技术有限公司 2023-02-28 — — CN disclosed
WO-2023280227-A2 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PROFOUNDBIO US CO. (US) 2023-01-12 — — WO disclosed
CN-110799547-A Compounds for treating, ameliorating or preventing neurological-related disorders and uses thereof 拜西欧斯（北京）生物技术有限公司 2020-02-14 — — CN disclosed
US-20150314008-A1 AURISTATIN COMPOUNDS AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. 2015-11-05 — — US disclosed
EP-2928503-A1 AURISTATIN COMPOUNDS AND CONJUGATES THEREOF Mersana Therapeutics, Inc. (US) 2015-10-14 — — EP disclosed
EP-2842575-A1 Auristatin drug linker conjugates Seattle Genetics, Inc. (US) 2015-03-04 — — EP disclosed
EP-2265283-B1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS INC (US) 2014-09-03 — — EP disclosed
WO-2014093379-A1 AURISTATIN COMPOUNDS AND CONJUGATES THEREOF MERSANA THERAPEUTICS, INC. (US) 2014-06-19 — — WO disclosed
US-20140050746-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2014-02-20 — — US disclosed
US-8609105-B2 Auristatin drug linker conjugates SEATTLE GENETICS, INC. (US) 2013-12-17 — — US disclosed
US-20110020343-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2011-01-27 — — US disclosed
EP-2265283-A1 AURISTATIN DRUG LINKER CONJUGATES Seattle Genetics, Inc. (US) 2010-12-29 — — EP disclosed
WO-2009117531-A1 AURISTATIN DRUG LINKER CONJUGATES SEATTLE GENETICS, INC. (US) 2009-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207418-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PAICS, DHFR, CD44 ALDH1A1 820/4885L3MBTL1 1722/4885FPR2 2007/4885
US-20110020343-A1 AURISTATIN DRUG LINKER CONJUGATES AURKA, AURKC, AURKB ALDH1A1 1466/4885L3MBTL1 948/4885FPR2 4302/4885
US-20140050746-A1 AURISTATIN DRUG LINKER CONJUGATES AURKA, AURKC, AURKB ALDH1A1 1466/4885L3MBTL1 948/4885FPR2 4302/4885
US-20240207429-A1 LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME PAICS, DHFR, CD44 ALDH1A1 820/4885L3MBTL1 1722/4885FPR2 2007/4885
US-20150314008-A1 AURISTATIN COMPOUNDS AND CONJUGATES THEREOF PBRM1, BRWD1, BRDT ALDH1A1 2233/4885L3MBTL1 620/4885FPR2 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.